## Aspirin® in cardiovascular indications including primary prevention indications

+--------+------------------------------+------------------------------+
| **Cou  | **Indication**               | **Dosage**                   |
| ntry** |                              |                              |
+--------+------------------------------+------------------------------+
| #      | Against platelet             | **Adults:** For prevention   |
| ## Arg | aggregation. Inhibition of   | of platelet aggregation it   |
| entina | platelet aggregation in all  | is recommended 1 tablet      |
|        | clinical situations          | daily. If necessary, the     |
| 100 mg | required.                    | dose could be modified. The  |
| micro- |                              | tablets of Cardioaspirina    |
|        | Against pain, fever, and     | should be chewed or          |
| caps   | swelling, against platelet   | swallowed with any kind of   |
| ulated | aggregation.                 | liquid.                      |
|        |                              |                              |
| 100 mg | BAYASPIRINA Prevent smoothes | **Adults:** For prevention   |
| t      | pains, lowers temperature    | of platelet aggregation it   |
| ablets | and smoothes symptoms that   | is recommended 1 tablet      |
|        | are associated to grippal    | daily. If necessary, the     |
| (Bayas | state and accompanied by     | dose could be modified. The  |
| pirina | malaise and/or fever. It is  | tablets of Bayaspirina       |
| Pr     | indicated for the temporary  | Prevent should be chewed or  |
| event) | relief of mild pains,        | swallowed with any kind of   |
|        | headaches and fever due to   | liquid.                      |
|        | cold, sore throat, and       |                              |
|        | dentition. BAYASPIRINA       | **Children:** Against pain,  |
|        | Prevent is indicated in all  | fever, and swelling\...      |
|        | cases where an effect        |                              |
|        | against platelet aggregation |                              |
|        | is needed.                   |                              |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| ### B  | [Prevention]{.underline}:    | In the cardio- and the       |
| elgium |                              | cerebro-vascular             |
|        | Secondary prevention after   | indications, clinical        |
| 100 mg | myocardial infarction,       | studies have not yet         |
| e. c.  | transient ischemic attacks   | demonstrated the optimal     |
|        | (TIA) or other cerebral      | dosage and duration of       |
|        | vascular incidents and       | therapy.                     |
|        | Kawasaki-syndrome.           |                              |
|        |                              | -   In the treatment of      |
|        | Primary prevention of        |     myocardial infarction    |
|        | myocardial infarction in     |     and unstable angina      |
|        | certain risk populations     |     pectoris: (100 to 300 mg |
|        | (serious familial            |     per day)                 |
|        | atherosclerotic antecedents; |                              |
|        | diabetes mellitus; gout;     | 1 to 3 tablets spread over   |
|        | hypertension;                | the day                      |
|        | dyslipidaemia).              |                              |
|        |                              | For acute myocardial         |
|        | While treating coronary risk | infarction the first dose    |
|        | factors, Cardioaspirine® is  | ad-                          |
|        | to be seen as an additive    |                              |
|        | and not as an alternative    | ministered should lie        |
|        | medication in the global     | between 300 mg and 600 mg    |
|        | treatment.                   |                              |
|        |                              | (see also recommendations in |
|        |                              | the section ("Mode           |
|        |                              |                              |
|        |                              | of administration").         |
|        |                              |                              |
|        |                              | -   As primary prevention of |
|        |                              |     myocardial infarction in |
|        |                              |     patients with risk       |
|        |                              |     factors:                 |
|        |                              |                              |
|        |                              | 1 to 2 tablets per day       |
|        |                              |                              |
|        |                              | -   As secondary prevention  |
|        |                              |     of myocardial infarction |
|        |                              |     (prevention of           |
|        |                              |     myocardial infarction    |
|        |                              |     recurrences), after TIA  |
|        |                              |     or another CVA:          |
|        |                              |                              |
|        |                              | 1 to 2 tablets per day       |
+--------+------------------------------+------------------------------+
| ###    | -   Unstable angina pectoris |                              |
|  Belo  |                              |                              |
| Russia | -   In patients with         |                              |
|        |     suspected acute          |                              |
| 100 mg |     myocardial infarction    |                              |
| e.c.   |                              |                              |
|        | -   Prophylaxis of repeated  |                              |
|        |     myocardial infarction    |                              |
|        |                              |                              |
|        | -   Condition after vascular |                              |
|        |     surgery (e.g. PTCA,      |                              |
|        |     CABG)                    |                              |
|        |                              |                              |
|        | -   Prophylaxis of transient |                              |
|        |     ischemic attacks and     |                              |
|        |     stroke in the period of  |                              |
|        |     initial symptoms         |                              |
|        |                              |                              |
|        | -   Prophylaxis of coronary  |                              |
|        |     thrombosis in patients   |                              |
|        |     with multiple risk       |                              |
|        |     factors                  |                              |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| ###    | Inhibition of platelet       |                              |
| Brazil | aggregation:                 |                              |
|        |                              |                              |
| 100 +  | -   in unstable angina       |                              |
| 300 mg |     pectoris;                |                              |
|        |                              |                              |
| e\. c. | -   in acute myocardial      |                              |
|        |     infarction;              |                              |
|        |                              |                              |
|        | -   in reinfarction          |                              |
|        |     prophylaxis;             |                              |
|        |                              |                              |
|        | -   after vascular surgery   |                              |
|        |     or interventions (e. g.  |                              |
|        |     PTCA, CABG);             |                              |
|        |                              |                              |
|        | -   for the prevention of    |                              |
|        |     transient ischaemic      |                              |
|        |     attacks and cerebral     |                              |
|        |     infarction;              |                              |
|        |                              |                              |
|        | -   to prevent thrombosis of |                              |
|        |     the coronary blood       |                              |
|        |     vessels in patients with |                              |
|        |     multiple risk factors;   |                              |
|        |                              |                              |
|        | -   to prevent venous        |                              |
|        |     thrombosis and lung      |                              |
|        |     embolism.                |                              |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| ###    | #                            | #### Pl                      |
| Canada | ##### Professional labelling | atelet aggregation inhibitor |
|        |                              |                              |
| 81 mg  | Aspirin is also indicated    | #### Suspected               |
| e.c.   | for the following uses,      | Acute Myocardial infarction: |
|        | based on its platelet        |                              |
|        | aggregation inhibitory       | An initial dose of at least  |
|        | properties:                  | 160 - 162,5 mg chewed or     |
|        |                              | crushed to ensure rapid      |
|        | -   for reducing the risk of | absorption as soon as a      |
|        |     vascular mortality in    | myocardial infarction is     |
|        |     patients with a          | suspected. The same dose     |
|        |     suspected acute          | should be given as           |
|        |     myocardial infarction;   | maintenance over the next 30 |
|        |                              | days. After 30 days,         |
|        | -   for reducing the risk of | consider further therapy     |
|        |     morbidity and death in   | based on dosage and          |
|        |     patients with unstable   | administration for           |
|        |     angina and in those with | prevention of recurrent MI   |
|        |     previous myocardial      | (see [Prior Myocardial       |
|        |     infarction;              | Infarction).]{.underline}    |
|        |                              |                              |
|        | -   for reducing the risk of | ####                         |
|        |     transient ischemic       | Prior Myocardial Infarction  |
|        |     attacks (TIA and for     | or Unstable Angina Pectoris: |
|        |     secondary prevention of  |                              |
|        |     atherothrombotic         | 80 - 325 mg daily according  |
|        |     cerebral infarction;     | to the individual needs of   |
|        |                              | the patient, as determined   |
|        | -   for prophylaxis of       | by the physician.            |
|        |     venous thromboembolism   |                              |
|        |     after total hip          | Transient Ischemic Attack    |
|        |     replacement;             | and Secondary Prevention of  |
|        |                              | Ahterothrombotic Cerebral    |
|        | ### fo                       | Infarction:                  |
|        | r reduction of adhesive prop |                              |
|        | erties of platelets in patie | 80 - 325 mg daily according  |
|        | nts following carotid endart | tot the individual needs of  |
|        | erectomy to prevent recurren | the patient, as determined   |
|        | ce of TIA and in hemodialysi | by the physician.            |
|        | s patients with a silicone r |                              |
|        | ubber arteriovenous cannula. |                              |
|        |                              |                              |
|        | ### For reduc                |                              |
|        | ing the risk of a first non- |                              |
|        | fatal myocardial infarction  |                              |
|        | in individuals deemed to be  |                              |
|        | at sufficient risk of such a |                              |
|        | n event by their physician". |                              |
|        |                              |                              |
|        | -   There is no evidence for |                              |
|        |     a reduction in the risk  |                              |
|        |     of first fatal           |                              |
|        |     myocardial infarction.   |                              |
|        |     Aspirin does not reduce  |                              |
|        |     the risk of either       |                              |
|        |     cardiovascular mortality |                              |
|        |     or first strokes, fatal  |                              |
|        |     or non-fatal.            |                              |
|        |                              |                              |
|        | ### The decrease             |                              |
|        | in the risk of first non-fat |                              |
|        | al myocardial infarction mus |                              |
|        | t be assessed against a much |                              |
|        |  smaller but not insignifica |                              |
|        | nt increase in the risk of h |                              |
|        | aemorrhagic stroke as well a |                              |
|        | s gastrointestinal bleeding. |                              |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| Canada | ##                           | Prophylaxis of Venous        |
| \...   | ## **2. Consumer labelling** | Thromboembolism after total  |
|        |                              | hip replacement:             |
|        | ### Coate                    |                              |
|        | d Aspirin Daily Low can help | 650 mg twice a day (1,300 mg |
|        |  save life in two different  | daily), started 1 day before |
|        | situations - to help prevent | surgery and continued for 14 |
|        |  a second heart attack or st | days.                        |
|        | roke, or when you suspect yo |                              |
|        | u are having a heart attack. | For other platelet           |
|        |                              | aggregation inhibitory uses: |
|        | ##                           |                              |
|        | ## Use during a heart attack | 325 - 1300 mg daily,         |
|        |                              | according to individual      |
|        | If you think you are having  | needs and generally accepted |
|        | a heart attack, you should   | standards of care for each   |
|        | immediately chew or crush    | indication.                  |
|        | 2 - 81 mg Coated Aspirin     |                              |
|        | Daily Low Dose tablets and   |                              |
|        | call an ambulance. It is     |                              |
|        | important to chew or crush   |                              |
|        | the product, to ensure this  |                              |
|        | medicine quickly works. Then |                              |
|        | get to a hospital            |                              |
|        | immediately for medical      |                              |
|        | attention.                   |                              |
|        |                              |                              |
|        | Taking Coated Aspirin Daily  |                              |
|        | Low Dose at the first signs  |                              |
|        | and symptoms can reduce your |                              |
|        | risk of dying from the heart |                              |
|        | attack. The signs and        |                              |
|        | symptoms of a heart attack   |                              |
|        | include:                     |                              |
|        |                              |                              |
|        | -   uncomfortable pressure,  |                              |
|        |     fullness, squeezing or   |                              |
|        |     pain in the center of    |                              |
|        |     the chest that lasts     |                              |
|        |     more than a few minutes, |                              |
|        |     or goes away quickly and |                              |
|        |     comes back,              |                              |
|        |                              |                              |
|        | -   pain that spreads to the |                              |
|        |     shoulders, neck or arms, |                              |
|        |                              |                              |
|        | -   chest discomfort with    |                              |
|        |     lightheadedness,         |                              |
|        |     fainting, sweating,      |                              |
|        |     nausea or shortness of   |                              |
|        |     breath.                  |                              |
|        |                              |                              |
|        | At the hospital, the doctor  |                              |
|        | will then recommend          |                              |
|        | appropriate therapy.         |                              |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
|        | Use to prevent a second      |                              |
|        | heart attack or stroke       |                              |
|        | (daily therapy)              |                              |
|        |                              |                              |
|        | Your doctor may recommend    |                              |
|        | you take Coated Aspirin      |                              |
|        | Daily Low Dose daily to help |                              |
|        | prevent a second heart       |                              |
|        | attack or stroke. After      |                              |
|        | having experienced a first   |                              |
|        | heart attack or stroke, you  |                              |
|        | can be at increased risk of  |                              |
|        | experiencing a second one.   |                              |
|        | You may also be at risk for  |                              |
|        | heart disease and stroke     |                              |
|        | because you may be           |                              |
|        | overweight, a smoker, have   |                              |
|        | an inactive lifestyle, high  |                              |
|        | blood pressure, are under    |                              |
|        | stress or have high blood    |                              |
|        | cholesterol.                 |                              |
|        |                              |                              |
|        | Following your doctors       |                              |
|        | instructions concerning the  |                              |
|        | use of Coated Aspirin Daily  |                              |
|        | Low Dose and the changes in  |                              |
|        | diet, exercise and lifestyle |                              |
|        | he/she may have prescribed,  |                              |
|        | will provide you with your   |                              |
|        | best opportunity to avoid    |                              |
|        | experiencing a second heart  |                              |
|        | attack or stroke. Always     |                              |
|        | contact you doctor if you    |                              |
|        | experience any difficulties. |                              |
+--------+------------------------------+------------------------------+
| ###    | Platelet aggregation         |                              |
|  Chile | inhibition,                  |                              |
|        |                              |                              |
| 100 mg | in acute myocardial          |                              |
|        | infarction                   |                              |
| micro  |                              |                              |
| e      | to prevent the thrombosis of |                              |
| ncaps. | the coronary blood vessles   |                              |
|        | in patients with multiple    |                              |
|        | risk factors.                |                              |
+--------+------------------------------+------------------------------+
| ### Co | -   Inhibition of platelet   | -   In unstable angina       |
| lombia |     aggregation              |     pectoris, in             |
|        |                              |     reinfarction             |
| 100 mg | -   in unstable angina       |     prophylaxis, after       |
| e. c.  |     pectoris                 |     arterial surgery or      |
|        |                              |     interventions: Daily     |
|        | -   in acute myocardial      |     doses of 100 -- 300 mg   |
|        |     infarction               |     ASA are recommended.     |
|        |                              |                              |
|        | -   in reinfarction          | -   In acute myocardial      |
|        |     prophylaxis              |     infarction: Daily doses  |
|        |                              |     of 100 -- 160 mg ASA are |
|        | -   after vascular surgery   |     recommended.             |
|        |     or interventions (e.g.   |                              |
|        |     PTCA, CABG)              | -   The first tablet should  |
|        |                              |     be chewed in order to    |
|        | -   for the prevention of    |     achieve fast absorption. |
|        |     transient ischemic       |                              |
|        |     attacks (TIA) and        | -   For the prevention of    |
|        |     cerebral infarction      |     transient ischemic       |
|        |     after the onset of       |     attacks and cerebral     |
|        |     precursor stages         |     infarction after the     |
|        |                              |     onset of precursor       |
|        | -   to prevent thrombosis of |     stages: Daily doses of   |
|        |     the coronary blood       |     30 -- 300 mg ASA are     |
|        |     vessels in patients with |     recommended.             |
|        |     multiple risk factors    |                              |
|        |                              | -   For the prevention of    |
|        | -   to prevent venous        |     thrombosis of the        |
|        |     thrombosis and lung      |     coronary blood vessels   |
|        |     embolism                 |     in patients with         |
|        |                              |     multiple risk factors:   |
|        | -   for long-term            |     Doses of 100 -- 200      |
|        |     prophylaxis of migraine  |     mg/daily or 300 mg every |
|        |                              |     other day are            |
|        | -   for reducing the risk of |     recommended.             |
|        |     first myocardial         |                              |
|        |     infarction in people     | -   For the prevention of    |
|        |     with cardiovascular risk |     venous thrombosis and    |
|        |     factors, elg. diabetes   |     lung embolism: Daily     |
|        |     mellitus,                |     doses of 100 --1500 mg   |
|        |     hyperlipidemia,          |     are recommended.         |
|        |     hypertension, obesity,   |                              |
|        |     smoking, old age.        |                              |
+--------+------------------------------+------------------------------+
| ### D  | Prophylactic against         | Adults: 100 mg daily         |
| enmark | arterial thrombosis.         |                              |
|        |                              |                              |
| 100 mg |                              |                              |
| e. c.  |                              |                              |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| ### E  | -   Inhibition of platelet   | -   In unstable angina       |
| cuador |     aggregation              |     pectoris, in             |
|        |                              |     reinfarction             |
| 100 mg | -   in unstable angina       |     prophylaxis, after       |
| e. c.  |     pectoris                 |     arterial surgery or      |
|        |                              |     interventions: Daily     |
|        | -   in acute myocardial      |     doses of 100 -- 300 mg   |
|        |     infarction               |     ASA are recommended.     |
|        |                              |                              |
|        | -   in reinfarction          | -   In acute myocardial      |
|        |     prophylaxis              |     infarction: Daily doses  |
|        |                              |     of 100 -- 160 mg ASA are |
|        | -   after vascular surgery   |     recommended.             |
|        |     or interventions (e.g.   |                              |
|        |     PTCA, CABG)              | -   The first tablet should  |
|        |                              |     be chewed in order to    |
|        | -   for the prevention of    |     achieve fast absorption. |
|        |     transient ischemic       |                              |
|        |     attacks (TIA) and        | -   For the prevention of    |
|        |     cerebral infarction      |     transient ischemic       |
|        |     after the onset of       |     attacks and cerebral     |
|        |     precursor stages         |     infarction after the     |
|        |                              |     onset of precursor       |
|        | -   to prevent thrombosis of |     stages: Daily doses of   |
|        |     the coronary blood       |     30 -- 300 mg ASA are     |
|        |     vessels in patients with |     recommended.             |
|        |     multiple risk factors    |                              |
|        |                              | -   For the prevention of    |
|        | -   to prevent venous        |     thrombosis of the        |
|        |     thrombosis and lung      |     coronary blood vessels   |
|        |     embolism                 |     in patients with         |
|        |                              |     multiple risk factors:   |
|        | -   for long-term            |     Doses of 100 -- 200      |
|        |     prophylaxis of migraine  |     mg/daily or 300 mg every |
|        |                              |     other day are            |
|        | -   for reducing the risk of |     recommended.             |
|        |     first myocardial         |                              |
|        |     infarction in people     | -   For the prevention of    |
|        |     with cardiovascular risk |     venous thrombosis and    |
|        |     factors, elg. diabetes   |     lung embolism: Daily     |
|        |     mellitus,                |     doses of 100 --1500 mg   |
|        |     hyperlipidemia,          |     are recommended.         |
|        |     hypertension, obesity,   |                              |
|        |     smoking, old age.        |                              |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| ### G  | -   Unstable angina pectoris | #####                        |
| eorgia |                              |                              |
|        | -   In patients with         |                              |
| 100 mg |     suspected acute          |                              |
| e. c.  |     myocardial infarction    |                              |
|        |                              |                              |
|        | -   Prophylaxis of repeated  |                              |
|        |     myocardial infarction    |                              |
|        |                              |                              |
|        | -   Condition after vascular |                              |
|        |     surgery (e.g. PTCA,      |                              |
|        |     CABG)                    |                              |
|        |                              |                              |
|        | -   Prophylaxis of transient |                              |
|        |     ischemic attacks and     |                              |
|        |     stroke in the period of  |                              |
|        |     initial symptoms         |                              |
|        |                              |                              |
|        | -   Prophylaxis of coronary  |                              |
|        |     thrombosis in patients   |                              |
|        |     with multiple risk       |                              |
|        |     factors                  |                              |
+--------+------------------------------+------------------------------+
| ###    | -   For the reduction of     | ##### Prophylaxis from re    |
| Greece |     risks resulting from the | occurrence of ischaemic thro |
|        |     reoccurence of ischaemic | mbotic cerebral attacks: 160 |
| 100 mg |     thrombolic cerebral      | -325 mg daily depending on t |
| e. c.  |     attacks in men. (In      | he condition of the patient. |
| /      |     woman the reduction of   |                              |
|        |     these risks has not been | Prophylaxis from thrombosis  |
| 300 mg |     confirmed).              | and cardiac ailments:        |
| e. c.  |                              |                              |
|        | -   Prophylaxis from         | Following a heart attack it  |
|        |     reoccurence of           | is administered in doses of  |
|        |     infarction.              | 150 mg/day for 1 month       |
|        |                              | following the episode. After |
|        | -   Unstable angina.         | by-pass operation it is      |
|        |                              | administered in doses of 75  |
|        | -   Prophylaxis from         | -100 mg/day.                 |
|        |     coronary thrombotic      |                              |
|        |     attacks in multi-risk    | #####                        |
|        |     patients (i. e.          |                              |
|        |     hypertensive or          |                              |
|        |     hyperlipidaemic          |                              |
|        |     patients, in diabetes    |                              |
|        |     (i. e. hypertensive or   |                              |
|        |     hyperlipidaemic          |                              |
|        |     patients, in diabetes    |                              |
|        |     mellitus and in          |                              |
|        |     excessive smoking).      |                              |
|        |                              |                              |
|        | -   Prophylaxis from         |                              |
|        |     thrombosis (prevention   |                              |
|        |     of re-coagulation) after |                              |
|        |     aortic-coronary by-pass  |                              |
|        |     and artificial           |                              |
|        |     arteriovenous            |                              |
|        |     inoculation in patients  |                              |
|        |     under haemodialysis.     |                              |
|        |                              |                              |
|        | -   Prevention of thrombosis |                              |
|        |     after percutaneous       |                              |
|        |     transluminal coronary    |                              |
|        |     angioplasty (PTCA).      |                              |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| ###    | Prevention of coronary       | Unless otherwise prescribed, |
|  Italy | thrombosis: after myocardial | a dosage of 1 tablet (100mg) |
|        | infarction, in patients with | per day is recommended in a  |
| 100 mg | unstable angina pectoris,    | single administration.       |
| e. c.  | chronic stable angina and in |                              |
|        | patients with multiple risk  |                              |
|        | factors (arterial            |                              |
|        | hypertension,                |                              |
|        | hypercholesterolaemia,       |                              |
|        | obesity, diabetes mellitus   |                              |
|        | and family history of        |                              |
|        | ischaemic cardiopathy).      |                              |
|        |                              |                              |
|        | Prevention of occlusive      |                              |
|        | ischaemic events in patients |                              |
|        | with transitory ischaemic    |                              |
|        | attacks (TIA) and after      |                              |
|        | stroke.                      |                              |
|        |                              |                              |
|        | Prevention of reocclusion    |                              |
|        | after aorto-coronary bypass, |                              |
|        | and in percutaneous          |                              |
|        | transluminal coronary        |                              |
|        | angioplasty (PTCA).          |                              |
|        | Prevention of thrombosis     |                              |
|        | during extracorporeal        |                              |
|        | circulation in patients in   |                              |
|        | haemodialysis and in         |                              |
|        | Kawasaki's syndrome.         |                              |
+--------+------------------------------+------------------------------+
| ##     | -   Unstable angina pectoris | -                            |
| # Kaza |                              |                              |
| khstan | -   In patients with         |                              |
|        |     suspected acute          |                              |
| 100 mg |     myocardial infarction    |                              |
| e c.   |                              |                              |
|        | -   Prophylaxis of repeated  |                              |
|        |     myocardial infarction    |                              |
|        |                              |                              |
|        | -   Condition after vascular |                              |
|        |     surgery (e.g. PTCA,      |                              |
|        |     CABG)                    |                              |
|        |                              |                              |
|        | -   Prophylaxis of transient |                              |
|        |     ischemic attacks and     |                              |
|        |     stroke in the period of  |                              |
|        |     initial symptoms         |                              |
|        |                              |                              |
|        | -   Prophylaxis of coronary  |                              |
|        |     thrombosis in patients   |                              |
|        |     with multiple risk       |                              |
|        |     factors                  |                              |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| ###    | -   Risk reduction of        | -   Risk reduction of        |
|  Korea |     non-fatal myocardial     |     non-fatal myocardial     |
|        |     infarction in patients   |     infarction in patients   |
| 100 mg |     with unstable angina,    |     with unstable angina:    |
|        |     and risk reduction of    |     75-300 mg daily.         |
|        |     transient ischemic       |                              |
|        |     attacks (TIAs) by the    | -   Risk reduction of        |
|        |     inhibitory action of     |     transient ischemic       |
|        |     platelet aggregation.    |     attacks (TIAs): 30-300   |
|        |                              |     mg daily.                |
|        | ```{=html}                   |                              |
|        | <!-- -->                     | -   Prevention of            |
|        | ```                          |     reinfarction after       |
|        | -   Prevention of            |     primary myocardial       |
|        |     reinfarction after       |     infarction: 300 mg       |
|        |     primary myocardial       |     daily.                   |
|        |     infarction.              |                              |
|        |                              | -   Inhibition of            |
|        | ```{=html}                   |     thromboembolism for the  |
|        | <!-- -->                     |     following cases:         |
|        | ```                          |                              |
|        | -   Inhibition of            | ```{=html}                   |
|        |     thromboembolism for the  | <!-- -->                     |
|        |     following cases:         | ```                          |
|        |                              | -   Cerebral infarction: 100 |
|        | ```{=html}                   |     mg once a day, increase  |
|        | <!-- -->                     |     up to 300 mg according   |
|        | ```                          |     to patient's symptom     |
|        | -   Cerebral infarction      |                              |
|        |                              | -   After coronary artery    |
|        | -   After coronary artery    |     bypass grafting (CABG)   |
|        |     bypass grafting (CABG)   |     or percutaneous          |
|        |     or percutaneous          |     transluminal coronary    |
|        |     transluminal coronary    |     angioplasty (PTCA): 100  |
|        |     angioplasty (PTCA)       |     mg once a day, increase  |
|        |                              |     up to 300 mg according   |
|        | Prevention of coronary       |     to patient's symptom. It |
|        | thrombosis in patients with  |     is advised to use many   |
|        | multiple risk factors        |     times of the usual       |
|        | (arterial hypertension,      |     dosage in early          |
|        | hypercholesterolaemia,       |     treatment of patients    |
|        | obesity, diabetes mellitus   |     received PTCA operation. |
|        | and family history of        |                              |
|        | ischaemic cardiopathy        | 100 mg once a day            |
+--------+------------------------------+------------------------------+
| ###    | Antiplatelet effect. Useful  |                              |
| Mexico | in patients with high risk   |                              |
|        | of dep venous thrombosis,    |                              |
| 100 mg | pulmonary embolism and       |                              |
|        | thrombophlebitits.           |                              |
| micro- |                              |                              |
|        | Due to it's antiplatelet     |                              |
| encaps | effect is recommended to     |                              |
| ulated | prevent an acute myocardial  |                              |
|        | infarction in patients with  |                              |
|        | high risk and is indicated   |                              |
|        | to reduce the risk of        |                              |
|        | ischaemic attack and stroke. |                              |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| ###    |                              | [Thrombose prophylaxis in    |
| Norway |                              | coronary vessels in patients |
|        |                              | with possible multiple risk  |
| 100 mg |                              | factors:]{.underline}        |
| e. c.  |                              |                              |
|        |                              | 100-200 mg daily or 300 mg   |
|        |                              | every second day is          |
|        |                              | recommended                  |
+--------+------------------------------+------------------------------+
| ##     | Platelet anti-aggregant,     |                              |
| # Peru | analgesic and                |                              |
|        | anti-inflammaory, ischemic   |                              |
| 100 mg | attack prophylaxis, brain    |                              |
| e. c.  | thromboembolism prophylaxis, |                              |
|        | recurrent brain              |                              |
|        | thromboembolism prophylaxis, |                              |
|        | myocardial infarction        |                              |
|        | prophylaxis, thromboembolism |                              |
|        | (prophylaxis) and treatment  |                              |
|        | of Kawasaki's disease.       |                              |
|        | Prevention of myocardial     |                              |
|        | infarction recurrence,       |                              |
|        | unstable angina, to maintain |                              |
|        | permeability after coronary  |                              |
|        | angioplasty or peripheral    |                              |
|        | vessel insufficiency caused  |                              |
|        | by arteriosclerosis.         |                              |
|        |                              |                              |
|        | To reduce the risk of        |                              |
|        | myocardial infarction in     |                              |
|        | people with cardiovascular   |                              |
|        | risk factor, for example     |                              |
|        | Diabetes mellitus,           |                              |
|        | hyperlipidemia,              |                              |
|        | hypertension, obesity,       |                              |
|        | smokers and old-aged people  |                              |
+--------+------------------------------+------------------------------+
| ###    | For the prophylaxis of       |                              |
|  Phili | thromboembolic disorders in  |                              |
| ppines | preventing myocardial        |                              |
|        | infarction and transient     |                              |
| 100 mg | ischaemic attack.            |                              |
| e. c.  |                              |                              |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| ###    | Inhibition of platelet       | [For the prevention of       |
| Poland | aggregation:                 | thrombosis of the coronary   |
|        |                              | blood vessels in patients    |
| 100 mg | -   to prevent thrombosis of | with multiple risk           |
| e. c.  |     the coronary blood       | factors:]{.underline}        |
|        |     vessels in patients with |                              |
|        |     multiple risk factors    | 1 tablet 100 mg daily        |
|        |                              |                              |
|        | -   to prevent venous        | [For the prevention of       |
|        |     thrombosis and lung      | venous thrombosis and lung   |
|        |     embolism                 | embolism:]{.underline}       |
|        |                              |                              |
|        |                              | 1-2 tablets 100 mg daily     |
+--------+------------------------------+------------------------------+
| ### Po | Inhibition of platelet       | [In unstable angina          |
| rtugal | aggregation:                 | pectoris, in reinfarction    |
|        |                              | prophylaxis, after arterial  |
| 100 mg | -   in unstable angina       | surgery or                   |
| e. c.  |     pectoris                 | interventions:]{.underline}  |
|        |                              |                              |
|        | -   in acute myocardial      | Daily doses of 100-300 mg    |
|        |     infarction               | acetylsalicylic acid are     |
|        |                              | recommended.                 |
|        | -   in reinfarction          |                              |
|        |     prophylaxis              | [In acute myocardial         |
|        |                              | infarction:]{.underline}     |
|        | -   after vascular surgery   |                              |
|        |     of interventions (e.g.   | Daily doses of 100-160 mg    |
|        |     PTCA, CABG)              | acetylsalicylic acid are     |
|        |                              | recommended. The first       |
|        | -   for the prevention of    | tablet should be chewed in   |
|        |     transient ischaemic      | order to achieve fast        |
|        |     attacks (TIA) and        | absorption.                  |
|        |     cerebral infarction      |                              |
|        |     after the onset of       | [For the prevention of       |
|        |     precursor stages         | transient ischaemic attacks  |
|        |                              | and cerebral infarction      |
|        | -   to prevent thrombosis of | after the onset of precursor |
|        |     the coronary blood       | stages:]{.underline}         |
|        |     vessels in patients with |                              |
|        |     multiple risk factors    | Daily doses of 30-300 mg     |
|        |                              | acetylsalicylic acid are     |
|        | -   to prevent venous        | recommended.                 |
|        |     thrombosis and lung      |                              |
|        |     embolism.                | [For the prevention of       |
|        |                              | thrombosis of the coronary   |
|        | > For long-term prophylaxis  | blood vessels in patients    |
|        | > of migraine.               | with multiple risk           |
|        |                              | factors:]{.underline}        |
|        |                              |                              |
|        |                              | Doses of 100-200 mg/daily or |
|        |                              | 300 mg every other day are   |
|        |                              | recommended.                 |
|        |                              |                              |
|        |                              | [For the prevention of       |
|        |                              | venous thrombosis and lung   |
|        |                              | embolism:]{.underline}       |
|        |                              |                              |
|        |                              | Daily doses of 1000 - 1500   |
|        |                              | mg are recommended.          |
|        |                              |                              |
|        |                              | [For prophylaxis of          |
|        |                              | migraine:]{.underline}       |
|        |                              |                              |
|        |                              | Doses of 100-200 mg/daily or |
|        |                              | 300 mg every other day are   |
|        |                              | recommended.                 |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| ###    | -   Unstable angina pectoris |                              |
| Russia |                              |                              |
|        | -   In patients with         |                              |
| 100 mg |     suspected acute          |                              |
| e. c.  |     myocardial infarction    |                              |
|        |                              |                              |
|        | -   Prophylaxis of repeated  |                              |
|        |     myocardial infarction    |                              |
|        |                              |                              |
|        | -   Condition after vascular |                              |
|        |     surgery (e.g. PTCA,      |                              |
|        |     CABG)                    |                              |
|        |                              |                              |
|        | -   Prophylaxis of transient |                              |
|        |     ischemic attacks and     |                              |
|        |     stroke in the period of  |                              |
|        |     initial symptoms         |                              |
|        |                              |                              |
|        | -   Prophylaxis of coronary  |                              |
|        |     thrombosis in patients   |                              |
|        |     with multiple risk       |                              |
|        |     factors                  |                              |
+--------+------------------------------+------------------------------+
| ### Sl | Aspirin protect 100 is used  | In unstable angina pectoris, |
| ovenia | to inhibit platelet          | in prevention of myocardial  |
|        | aggregation.                 | infarction recurrence, after |
| p      |                              | surgery or revascularization |
| rotect | -   In unstable angina       | in/on arteries: 100 - 300 mg |
| 100    |     pectoris                 | asa per day                  |
|        |                              |                              |
|        | -   In acute myocardial      | In acute myocardial          |
|        |     infarction               | infarction: 100 - 160 mg asa |
|        |                              | per day,                     |
|        | -   In prevention of         |                              |
|        |     myocardial infarction    | You must chew the first      |
|        |     relapse                  | tablet so that it is         |
|        |                              | absorbed quickly.            |
|        | -   After surgery or         |                              |
|        |     revascularization in/on  | In prevention of transitory  |
|        |     arteries (e.g. PTCA,     | ishemic attacks and strokes  |
|        |     by-pass)                 | in symptomatic patients:     |
|        |                              | 30 - 300 mg asa per day.     |
|        | -   In prevention of         |                              |
|        |     transitory ishemic       | In prevention of coronary    |
|        |     attacks (TIA) and        | heart disease in             |
|        |     strokes in symptomatic   | individuals, with several    |
|        |     patients                 | significant risk factors:    |
|        |                              | 100 - 200 mg per day or 300  |
|        | -   In prevention of         | mg every other day.          |
|        |     coronary heart disease   |                              |
|        |     in individuals, with     | In prevention of vein        |
|        |     several significant risk | thrombosis and pulmonary     |
|        |     factors                  | embolism: 1000 - 1500 mg per |
|        |                              | day.                         |
|        | -   In prevention of vein    |                              |
|        |     thrombosis and pulmonary | In prevention of migraine:   |
|        |     embolism                 | 100 - 200 mg per day or 300  |
|        |                              | mg every other day.          |
+--------+------------------------------+------------------------------+

+--------+------------------------------+------------------------------+
| ###    | Coraspin 100 is indicated as | For the prophylaxis of       |
| Turkey | antithrombotic; in the       | reinfarction and non-stable  |
|        | inflammation of superficial  | angina pectoris 1-3 x 1      |
|        | veins, non-stable angina     | tablet(s)/day                |
|        | pectoris and in patients at  |                              |
|        | risk (hypertensive,          | For the prevention of the    |
|        | hyperlipidemic and diabetic) | coronary thrombosis in       |
|        | for preventing coronary      | patients at risk 1-2 x 1     |
|        | thrombosis; for the          | tablet(s)/day                |
|        | prophylaxis of myocardial    |                              |
|        | reinfarction; for preventing | For the prophylaxis of       |
|        | post operative thrombosis    | post-operative thrombosis    |
|        | and embolism in              | 1x1 tablet/day               |
|        | cardiovascular surgery,      |                              |
|        | particularly in              | For the prophylaxis of       |
|        | aorto-coronary bypass and    | stroke, and transient        |
|        | arteriovenous shunts; in     | ischemic attacks 1-3 x 1     |
|        | transient ischemic attacks   | tablet(s)/day                |
|        | or for the prophylaxis of    |                              |
|        | stroke.                      |                              |
+--------+------------------------------+------------------------------+
| ### U  | -   Unstable angina pectoris |                              |
| kraine |                              |                              |
|        | -   In patients with         |                              |
| 100 mg |     suspected acute          |                              |
| e. c.  |     myocardial infarction    |                              |
|        |                              |                              |
|        | -   Prophylaxis of repeated  |                              |
|        |     myocardial infarction    |                              |
|        |                              |                              |
|        | -   Condition after vascular |                              |
|        |     surgery (e.g. PTCA,      |                              |
|        |     CABG)                    |                              |
|        |                              |                              |
|        | -   Prophylaxis of transient |                              |
|        |     ischemic attacks and     |                              |
|        |     stroke in the period of  |                              |
|        |     initial symptoms         |                              |
|        |                              |                              |
|        | -   Prophylaxis of coronary  |                              |
|        |     thrombosis in patients   |                              |
|        |     with multiple risk       |                              |
|        |     factors                  |                              |
+--------+------------------------------+------------------------------+
| ##     | -   Unstable angina pectoris |                              |
| # Uzbe |                              |                              |
| kistan | -   In patients with         |                              |
|        |     suspected acute          |                              |
| 100 mg |     myocardial infarction    |                              |
| e. c.  |                              |                              |
|        | -   Prophylaxis of repeated  |                              |
|        |     myocardial infarction    |                              |
|        |                              |                              |
|        | -   Condition after vascular |                              |
|        |     surgery (e.g. PTCA,      |                              |
|        |     CABG)                    |                              |
|        |                              |                              |
|        | -   Prophylaxis of transient |                              |
|        |     ischemic attacks and     |                              |
|        |     stroke in the period of  |                              |
|        |     initial symptoms         |                              |
|        |                              |                              |
|        | -   Prophylaxis of coronary  |                              |
|        |     thrombosis in patients   |                              |
|        |     with multiple risk       |                              |
|        |     factors                  |                              |
+--------+------------------------------+------------------------------+
| #      | As a antiplatelet agent in   | Adults: 1 tablet 81 mg / day |
| ## Ven | the primary and secondary    |                              |
| ezuela | cardiovascular diseases      |                              |
|        | prevention.                  |                              |
+--------+------------------------------+------------------------------+